Brought to you by:
AVF 2022: VenoValve improvement ‘maintained’ for 2.5 years without adverse events
Envveno Medical announced positive 30-month data from the first-in-human trial of the VenoValve bioprosthetic potential venous valve replacement during the 2022 American Venous Forum (AVF) annual meeting (VENOUS2022) held in Orlando, Florida (Feb. 23–26). The results showed that VenoValve recipients—now an…
VIVID study on Duo venous stent system now fully enrolled, Vesper Medical announces
Vesper Medical recently announced the completion of enrollment in its pivotal study—VIVID (Venous stent for the iliofemoral vein investigational clinical trial using the Vesper Duo venous stent system). VIVID enrolled its 160th patient earlier this month, marking completion of enrollment in the trial.…
Envveno Medical reports successful completion of first VenoValve surgery in US pivotal trial
Envveno Medical—formerly Hancock Jaffe Laboratories—recently announced that the first VenoValve surgery in the company’s SAVVE US pivotal trial for the VenoValve has been successfully completed. The surgery was performed by Adriana Laser, MD, associate professor of surgery at Albany Medical…
Colombian researchers report positive 24-month results for VenoValve
Promising two-year results for an emerging potential prosthetic venous valve replacement—which is about to commence a U.S. pivotal trial—were announced at the Vascular Annual Meeting (VAM) in San Diego on Thursday afternoon. Researchers from Bogota, Colombia, revealed that patients treated…
VenoValve granted FDA Breakthrough Device designation
Hancock Jaffe Laboratories today (Wednesday, Aug. 4) announced that the Food and Drug Administration (FDA) has granted Breakthrough Device Designation status to the company’s VenoValve device, a potential treatment option for chronic venous insufficiency (CVI). “We are very pleased to…
VenoValve: Chronic venous insufficiency device gains brisk double of first US patent, IDE approval
Hancock Jaffe Laboratories recently revealed that the United States Patent and Trademark Office (USPTO) issued the first patent covering the company’s VenoValve. The patent is entitled Implantable Vein Frame and is U.S. patent number 10,959,841. The company recently announced that only…
VenaSeal superior for management of chronic venous insufficiency, finds systematic review
According to a network meta-analysis, the VenaSeal system by Medtronic is “a promising therapeutic option for anatomic success at six months.” The study, published in the Journal of Vascular Surgery: Venous and Lymphatic Disorders, also highlighted the lower number of…